Residency · Residency · Vascular Surgery
Transfemoral Carotid Artery Stenting
Overview
Carotid artery stenting (CAS) serves as an endovascular alternative to carotid endarterectomy (CEA) for treating extracranial carotid artery stenosis. This procedure involves the transfemoral catheter-based deployment of a self-expanding stent at the carotid bifurcation. To minimize the risk of periprocedural stroke, embolic protection devices (EPDs) are essential during the intervention. CAS is particularly appropriate for select patients, especially those with hostile surgical anatomy that makes traditional surgery challenging.
Indications
Established Indications (CMS/SVS)
CAS is indicated for symptomatic stenosis of 50% or greater in patients who are at high surgical risk for CEA. This includes individuals with prior CEA who have recurrent stenosis, those who have undergone radical neck dissection or radiation therapy, lesions that are surgically inaccessible (such as those located above the C2 vertebra or below the clavicle), patients with contralateral laryngeal nerve palsy, and those with a tracheostomy. For asymptomatic stenosis of 80% or greater, CAS may be considered in high surgical risk patients, although this indication remains more controversial.
High Surgical Risk Criteria
Patients deemed high risk for surgery often have significant cardiac disease, such as a recent myocardial infarction, unstable angina, or severe congestive heart failure. Severe pulmonary disease, contralateral internal carotid artery (ICA) occlusion, prior neck surgery or radiation creating a hostile neck environment, and recurrent stenosis after prior CEA also categorize patients as high surgical risk.
Less Established
CAS in standard-risk symptomatic patients is less established, although the CREST trial demonstrated equivalence to CEA, noting that myocardial infarction was included in the combined endpoint. The role of CAS in asymptomatic standard-risk patients remains under investigation.
CREST Trial (Carotid Revascularization Endarterectomy vs. Stenting Trial)
The CREST trial enrolled 2,502 patients with symptomatic stenosis of 50% or greater and asymptomatic stenosis of 60% or greater. The primary endpoint, which included stroke, myocardial infarction, death, or ipsilateral stroke at four years, showed no significant difference between CAS and CEA. However, CAS was associated with a higher periprocedural stroke rate (4.1% versus 2.3%), while CEA had a higher periprocedural myocardial infarction rate (2.3% versus 1.1%) and a higher incidence of cranial nerve injury (4.8% versus 0.3%). Long-term follow-up revealed no difference in ipsilateral stroke rates at ten years. The interpretation of these results suggests that CAS is a reasonable alternative to CEA in appropriate patients, but the increased stroke risk with CAS must be carefully considered.
| Outcome | CAS | CEA | Interpretation |
|---|---|---|---|
| Periprocedural stroke | 4.1% | 2.3% | Higher with CAS |
| Periprocedural MI | 1.1% | 2.3% | Higher with CEA |
| Cranial nerve injury | 0.3% | 4.8% | Major CAS advantage |
| Primary composite endpoint (4 yr) | No significant difference | No significant difference | Equivalent overall |
| Long-term ipsilateral stroke (10 yr) | No difference | No difference | Equivalent durability |
Age Effect
The trial also demonstrated that CAS had higher periprocedural stroke rates in patients older than 70 years. This increased risk is related to more complex aortic arch anatomy, vessel tortuosity, and atheromatous disease in the elderly. Consequently, CEA is generally preferred in older patients.
<image>Diagram comparing transfemoral carotid artery stenting technique with carotid endarterectomy, showing the endovascular approach with femoral access, catheter navigation through the aortic arch to the carotid bifurcation with embolic protection device, versus the surgical approach with neck incision and direct plaque removal</image>
Technique
Access
The procedure typically begins with access through the common femoral artery, usually on the right side, using a 6-8 French sheath. A diagnostic aortogram and selective carotid angiography are performed to assess the anatomy of the aortic arch, which is classified into Types I through III based on complexity.
Arch Types
Type I arch anatomy is the simplest, with all great vessels originating at the apex of the arch. Type II arches have great vessels originating between the apex and a horizontal line through the top of the arch, while Type III arches are the most challenging, with great vessels originating below this horizontal line. The "bovine" arch variant adds further complexity. Type III arches and severe atheromatous disease of the aortic arch increase the risk of periprocedural embolization during catheter navigation.
Embolic Protection Devices (EPDs)
Embolic protection devices are critical to reduce the risk of cerebral embolization during CAS. The most common type is the distal filter device, such as FilterWire EZ, Spider FX, or Emboshield NAV6, which is deployed distal to the lesion to capture embolic debris during stenting. However, distal filters may not capture all particles and can be difficult to navigate past tight stenoses. Distal balloon occlusion devices like the GuardWire temporarily occlude the distal ICA during stenting, allowing debris to be aspirated before restoring flow, but this requires the patient to tolerate ICA occlusion. Proximal protection devices, such as the Mo.Ma device, use balloons to occlude the common carotid artery (CCA) and external carotid artery (ECA), reversing flow in the ICA to carry debris away from the brain. This method does not require crossing the lesion first and forms the basis of the transcarotid artery revascularization (TCAR) concept.
Procedural Steps
The procedure begins with femoral access and diagnostic angiography. A guiding catheter or sheath is then placed in the CCA. An embolic protection device is deployed distal to the lesion. Pre-dilation is performed using a low-profile balloon (3-4 mm) to facilitate stent passage. A self-expanding stent, sized appropriately to the CCA and ICA, is deployed across the lesion; common stents include Acculink, Precise, Wallstent, and XACT. Post-dilation with balloon angioplasty is then performed within the stent, typically using a 5-6 mm balloon for the ICA portion and 7-9 mm for the CCA portion. The embolic protection device is subsequently retrieved, and completion angiography, including intracranial views, is performed to assess for distal embolization.
Hemodynamic Management
Bradycardia and hypotension are common during balloon inflation at the carotid sinus due to baroreceptor stimulation. To mitigate these effects, pre-treatment with atropine is recommended, and vasopressors should be readily available. In rare cases, a temporary pacing catheter may be necessary. Maintaining adequate cerebral perfusion throughout the procedure is essential.
<image>Fluoroscopic sequence of transfemoral carotid artery stenting showing (A) selective carotid angiogram with high-grade ICA stenosis, (B) distal filter embolic protection device deployed, (C) self-expanding stent deployment across the bifurcation, (D) post-dilation, and (E) completion angiogram with widely patent ICA</image>
Post-Procedural Care
After the procedure, patients are monitored in a bed for 12 to 24 hours with frequent neurologic checks and hemodynamic monitoring. Blood pressure control is critical to avoid hypertension, which can lead to hyperperfusion syndrome, and hypotension, which increases the risk of stent thrombosis. Dual antiplatelet therapy, typically aspirin combined with clopidogrel, is administered for at least 30 days, with many clinicians continuing therapy for three to six months. Aspirin is continued indefinitely thereafter. Duplex ultrasound surveillance is performed at one month, six months, and then annually. It is important to note that in-stent velocity criteria differ from native vessel criteria because stents alter vessel compliance. Peak systolic velocity (PSV) greater than 220 cm/s or a PSV ratio above 2.7 may suggest in-stent restenosis.
Outcomes
Periprocedural stroke rates range from 3 to 5%, varying with operator experience and patient selection. The periprocedural myocardial infarction rate is approximately 1%, which is lower than that seen with CEA. Cranial nerve injury is essentially absent with CAS, representing a major advantage over CEA. In-stent restenosis occurs in 5 to 10% of cases at five years, although most are asymptomatic; repeat stenting or CEA may be necessary if clinically significant restenosis develops. Long-term ipsilateral stroke prevention with CAS is equivalent to that of CEA, as demonstrated in the CREST trial.
Controversies
Several controversies surround CAS. In standard-risk patients, the CREST trial showed composite equivalence between CAS and CEA but highlighted a higher stroke rate with CAS and a higher myocardial infarction rate with CEA, raising questions about which outcome is more clinically significant. The benefit of CAS in asymptomatic disease compared to modern medical therapy remains unproven. An age cutoff is debated, with CAS outcomes being worse in patients over 70 years old. Operator volume and credentialing are critical, as outcomes are highly operator-dependent. Additionally, dual antiplatelet therapy compliance is essential, with concerns about clopidogrel resistance and stent thrombosis.
Clinical Pearls
Carotid artery stenting is a technically demanding procedure, and outcomes depend heavily on operator experience; therefore, low-volume operators should refer patients to experienced centers. The anatomy of the aortic arch is important, as Type III arches and tortuous or atheromatous arches increase the risk of embolic events during catheter navigation. The use of an embolic protection device is mandatory because unprotected CAS is associated with significantly higher stroke rates. Pre-treatment with atropine before balloon dilation at the carotid bulb is crucial to prevent profound bradycardia or asystole. CAS is best suited for patients with hostile neck anatomy, such as those with prior CEA, radiation, or high lesions, or those with significant cardiac risk. In patients over 70 years old, CEA is generally preferred over transfemoral CAS due to the higher stroke risk associated with CAS in the elderly. Finally, ensuring compliance with dual antiplatelet therapy before the procedure is essential to reduce the risk of stent thrombosis.
References
- Brott TG, et al. Stenting vs. endarterectomy for treatment of carotid-artery stenosis (CREST). N Engl J Med. 2010;363(1):11-23.
- Brott TG, et al. Long-term results of stenting vs. endarterectomy (CREST). N Engl J Med. 2016;374(11):1021-1031.
- Yadav JS, et al. Protected carotid-artery stenting vs. endarterectomy in high-risk patients (SAPPHIRE). N Engl J Med. 2004;351(15):1493-1501.
- Ricotta JJ, et al. Updated SVS guidelines for management of extracranial carotid disease. J Vasc Surg. 2011;54(3):e1-e31.
- Naylor AR, et al. ESVS 2023 Guidelines on Carotid and Vertebral Artery Disease. Eur J Vasc Endovasc Surg. 2023;65(1):7-111.
